Abbott And Coroventis Partner To Address Often-Overlooked Microvascular Dysfunction
Coroventis’ CoroFlow software allows Abbott’s PressureWire X to diagnose coronary microvascular dysfunction caused by invisible blockages in the heart’s smallest arteries.
You may also be interested in...
Neovasc’ COO Bill Little talked to Medtech Insight about the company’s plans to develop its Reducer transcatheter device to treat cardiac angina associated with or without obstructive coronary disease.
The company’s survey of more than 1,400 patients, physicians and administrators showed patients want more personalized care and physicians want more data.
The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.